4.39

0.68% -0.03

Molecular Partners Ag Adr (MOLN)

Overview News Price History Discussions Forecast

Molecular Partners Ag Adr stock is traded at $4.39, with a volume of 658. It is down -0.68% in the last 24 hours and down -10.77% over the past month. Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Previous Close:

$4.42

Open:

$4.4

24h Volume:

658

Relative Volume:

0.06

Market Cap:

$161.88M

Revenue:

$7.80M

Net Income/Loss:

$-69.02M

P/E Ratio:

-2.0502

EPS:

-2.1413

Net Cash Flow:

$-66.61M

1W Performance:

-10.41%

1M Performance:

-10.77%

6M Performance:

-15.90%

1Y Performance:

+17.69%

1-Day Range:

$4.39

$4.40

1-Week Range:

$4.27

$5.10

52-Week Range:

$3.32

$12.70

Molecular Partners Ag Adr Stock (MOLN) Company Profile

Name

Molecular Partners Ag Adr

Sector

Healthcare (1169)

Industry

Biotechnology (679)

Phone

Address

Employee

159

Twitter

Next Earnings Date

2024-08-26

Latest SEC Filings

MOLN's Discussions on Twitter

Compare MOLN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MOLN Molecular Partners Ag Adr	4.39	161.88M	7.80M	-69.02M	-66.61M	-2.1413
VRTX Vertex Pharmaceuticals Inc	502.92	129.14B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	680.61	74.41B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	581.21	35.31B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	241.75	31.30B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	254.57	27.35B	3.32B	-860.46M	-1.04B	-8.32

Molecular Partners Ag Adr Stock (MOLN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-30-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-29-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
May-25-22	Upgrade	Credit Suisse	Underperform → Neutral
Apr-27-22	Downgrade	Credit Suisse	Neutral → Underperform
Jul-13-21	Initiated	Cowen	Outperform
Jul-12-21	Resumed	SVB Leerink	Outperform